BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/22/2022 10:52:23 AM | Browse: 238 | Download: 405
 |
Received |
|
2021-03-30 07:22 |
|
Peer-Review Started |
|
2021-03-30 07:32 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-27 02:20 |
|
Revised |
|
2021-09-22 14:39 |
|
Second Decision |
|
2022-04-02 02:09 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-04-04 06:34 |
|
Articles in Press |
|
2022-04-04 06:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-04-11 02:11 |
|
Publish the Manuscript Online |
|
2022-04-22 10:52 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marco Biolato, Mattia Paratore, Luca Di Gialleonardo, Giuseppe Marrone and Antonio Grieco |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marco Biolato, MD, PhD, Staff Physician, Internal and Liver Transplant Medicine Unit, CEMAD, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A Gemelli 8, Rome 00168, Italy. marco.biolato@policlinicogemelli.it |
| Key Words |
Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Bleeding |
| Core Tip |
The role of anticoagulant therapy in portal vein thrombosis is still unclear, especially in partial, chronic and asymptomatic thrombosis. Vitamin K antagonists and low-molecular-weight heparin were demonstrated to be safe and effective, with a positive influence on liver function, portal hypertension and mortality. Direct oral anticoagulants are a new approach to treat portal vein thrombosis in patients with cirrhosis and have many advantages compared to classic anticoagulants, although evidence is still limited. In patients awaiting liver transplantation, dabigatran may be promising for preventing thrombosis progression because of the low rate of hepatotoxicity, predominant renal metabolism and reversibility in perioperative management. |
| Publish Date |
2022-04-22 10:52 |
| Citation |
Biolato M, Paratore M, Di Gialleonardo L, Marrone G, Grieco A. Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence? World J Hepatol 2022; 14(4): 682-695 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i4/682.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i4.682 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
